LOW-DOSE CANDESARTAN IMPROVES RENAL BLOOD FLOW AND KIDNEY OXYGEN TENSION IN RATS WITH ENDOTOXIN-INDUCED ACUTE KIDNEY DYSFUNCTION

Shock ◽  
2007 ◽  
pp. 1 ◽  
Author(s):  
Nicoletta Nitescu ◽  
Elisabeth Grimberg ◽  
Gregor Guron
1985 ◽  
Vol 38 (6) ◽  
pp. 582-591 ◽  
Author(s):  
Mitchell P. Fink ◽  
Ronald Nelson ◽  
Rudolph Roethel
Keyword(s):  

2018 ◽  
Vol 315 (2) ◽  
pp. F241-F246
Author(s):  
Sofia Jönsson ◽  
Jacqueline M. Melville ◽  
Mediha Becirovic-Agic ◽  
Michael Hultström

Renin-angiotensin-system blockers are thought to increase the risk of acute kidney injury after surgery and hemorrhage. We found that losartan does not cause renal cortical hypoxia after hemorrhage in rats because of decreased renal vascular resistance, but we did not evaluate resuscitation. We aimed to study losartan’s effect on renal cortical and medullary oxygenation, as well as norepinephrine’s vasopressor effect in a model of resuscitated hemorrhage. After 7 days of losartan (60 mg·kg−1·day−1) or control treatment, male Wistar rats were hemorrhaged 20% of their blood volume and resuscitated with Ringerʼs acetate. Mean arterial pressure, renal blood flow, and kidney tissue oxygenation were measured at baseline and after resuscitation. Finally, the effect of norepinephrine on mean arterial pressure and renal blood flow was investigated. As expected, losartan lowered mean arterial pressure but not renal blood flow. Losartan did not affect renal oxygen consumption and oxygen tension. Mean arterial pressure and renal blood flow were lower after resuscitated hemorrhage. A smaller increase of renal vascular resistance in the losartan group translated to a smaller decrease in cortical oxygen tension, but no significant difference was seen in medullary oxygen tension, either between groups or after hemorrhage. The effect of norepinephrine on mean arterial pressure and renal blood flow was similar in control- and losartan-treated rats. Losartan does not decrease renal oxygenation after resuscitated hemorrhage because of a smaller increase in renal vascular resistance. Further, losartan does not decrease the efficiency of norepinephrine as a vasopressor, indicating that blood pressure may be managed effectively during losartan treatment.


2016 ◽  
Vol 594 (21) ◽  
pp. 6287-6300 ◽  
Author(s):  
Tonja W. Emans ◽  
Ben J. Janssen ◽  
Maximilian I. Pinkham ◽  
Connie P. C. Ow ◽  
Roger G. Evans ◽  
...  

2003 ◽  
Vol 44 (3) ◽  
pp. 347-353 ◽  
Author(s):  
F. Palm ◽  
P.-O. Carlsson ◽  
P. Hansell ◽  
O. Hellberg ◽  
A. Nygren ◽  
...  

1995 ◽  
Vol 23 (Supplement) ◽  
pp. A231
Author(s):  
Abhijit Lohe ◽  
John Kuluz ◽  
Barry Gelman ◽  
Ricardo Prado ◽  
Charles Schleien

Shock ◽  
2007 ◽  
pp. 1 ◽  
Author(s):  
Nicoletta Nitescu ◽  
Elisabeth Grimberg ◽  
Sven-Erik Ricksten ◽  
Hans Herlitz ◽  
Gregor Guron

1986 ◽  
Vol 20 (7-8) ◽  
pp. 543-546 ◽  
Author(s):  
Deborah K. Armstrong ◽  
Joseph F. Dasta ◽  
Thomas E. Reilley ◽  
Richard D. Tallman

Increasing renal blood flow (RBF) by the administration of low-dose dopamine is one mechanism to increase urine output in oliguric patients. This response is mediated in part by stimulation of dopaminergic receptors in the kidney, which could be attenuated by the dopamine blocker haloperidol. We evaluated this interaction by administering both drugs in clinically used doses to six anesthetized mongrel dogs. A dopamine regimen of 2.5 μg/kg/min significantly increased RBF along with cardiac output and stroke volume. Simultaneous administration of haloperidol 50 μg/kg iv did not influence the ability of low-dose dopamine to increase RBF. Although haloperidol is an antagonist of dopaminergic receptors, the increase in RBF associated with low-dose dopamine is maintained when intravenous haloperidol is concurrently administered to dogs.


Sign in / Sign up

Export Citation Format

Share Document